Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers

Rachael Z. Stolzenberg-Solomon, Paul John Limburg, Michael Pollak, Philip R. Taylor, Jarino Virtamo, Demetrius Albanes

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50-69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37-1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38-1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50-1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number3
StatePublished - Mar 2004

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Somatomedins
Pancreatic Neoplasms
Odds Ratio
Confidence Intervals
Logistic Models
Neoplasms
beta Carotene
alpha-Tocopherol
Serum
Case-Control Studies
Adenocarcinoma
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Population

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Stolzenberg-Solomon, R. Z., Limburg, P. J., Pollak, M., Taylor, P. R., Virtamo, J., & Albanes, D. (2004). Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiology Biomarkers and Prevention, 13(3), 438-444.

Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. / Stolzenberg-Solomon, Rachael Z.; Limburg, Paul John; Pollak, Michael; Taylor, Philip R.; Virtamo, Jarino; Albanes, Demetrius.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 3, 03.2004, p. 438-444.

Research output: Contribution to journalArticle

Stolzenberg-Solomon, RZ, Limburg, PJ, Pollak, M, Taylor, PR, Virtamo, J & Albanes, D 2004, 'Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers', Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 3, pp. 438-444.
Stolzenberg-Solomon, Rachael Z. ; Limburg, Paul John ; Pollak, Michael ; Taylor, Philip R. ; Virtamo, Jarino ; Albanes, Demetrius. / Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 3. pp. 438-444.
@article{575e7d1fa5be4691a4bd08f2b3e1d3f9,
title = "Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers",
abstract = "To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50-69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95{\%} confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95{\%} CI 0.37-1.21, P trend = 0.17; OR = 0.70, 95{\%} CI 0.38-1.27, P trend = 0.12; and OR = 0.85, 95{\%} CI 0.50-1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.",
author = "Stolzenberg-Solomon, {Rachael Z.} and Limburg, {Paul John} and Michael Pollak and Taylor, {Philip R.} and Jarino Virtamo and Demetrius Albanes",
year = "2004",
month = "3",
language = "English (US)",
volume = "13",
pages = "438--444",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers

AU - Stolzenberg-Solomon, Rachael Z.

AU - Limburg, Paul John

AU - Pollak, Michael

AU - Taylor, Philip R.

AU - Virtamo, Jarino

AU - Albanes, Demetrius

PY - 2004/3

Y1 - 2004/3

N2 - To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50-69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37-1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38-1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50-1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.

AB - To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50-69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37-1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38-1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50-1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.

UR - http://www.scopus.com/inward/record.url?scp=2442666848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442666848&partnerID=8YFLogxK

M3 - Article

C2 - 15006921

AN - SCOPUS:2442666848

VL - 13

SP - 438

EP - 444

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -